Home HPV Testing in Underscreened Women — A Work in Progress

Adding a mailed in-home HPV sample collection kit to mailed reminders for cervical cancer screening did not significantly increase CIN2+ detection among HMO enrollees, but a broader study is warranted.

More than half of U.S. cervical cancer diagnoses occur in women who were not screened at the recommended intervals. To test whether providing an in-home vaginal swab kit for human papillomavirus (HPV) testing would result in higher rates of detection and treatment of cervical intraepithelial neoplasia grade ≥2 (CIN2+; a cervical cancer precursor) than usual care (annual reminders), investigators randomized almost 20,000 women enrolled at Kaiser Permanente Washington (age range, 30–64; not screened within the past 3 years and 5 months) to usual care with an HPV self-sampling kit sent by mail (intervention) or without (control). All participants were followed for up to 18 months.

Although a significantly higher proportion of women in the inter…

Reviewing Author

Anna Wald, MD, MPH

Disclosures

Consultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)

RoyaltiesUpToDate

Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris

Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases

Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)